Drug Discovery World

MARCH 13, 2023

The cell and gene therapy (CGT) landscape has grown significantly in the past year. Between the 24 therapies already approved by the FDA 1 and a marked increase in clinical trials, widespread accessibility to precision medicine feels within reach. But now, the increased efficiency is likely making drug development cheaper.

Therapies 130

Therapies Drug Development Clinical Trials Cell Based Assays 130

PPD

SEPTEMBER 6, 2023

Approaches to outsourcing clinical trials have changed significantly in recent years. Mixing of service models — a strategy that drug developers are leveraging now more than ever — can bring life-changing therapies to market faster. Often working directly within client’s systems and SOPs.

Drug Development 98

Drug Development Clinical Trials Drugs Clinical Research 98

LifeSciVC

AUGUST 21, 2024

Drug development is a long process, and patients are waiting. Keeping ahead of schedule will help to maintain manufacturing efficiencies, ensure adequate supply and product quality, and meet development timelines. Don’t get me wrong. I know we all haven’t exactly been coasting this summer.

Clinical Trials 63

Clinical Trials Trials Disease Clinical Supply 63

Drug Target Review

SEPTEMBER 10, 2024

The current landscape of protein drug development is characterised by accelerated timelines where new drugs are approved in months rather than years. In recent years, the biopharmaceutical industry has identified rapid Toxicology (Tox) material supply as the new critical path to IND readiness.

Clinical Supply 64

Clinical Supply Drug Development Production Animal Testing 64

The Pharma Data

DECEMBER 4, 2021

The companies are exploring these advances through their newly created Pfizer Amazon Collaboration Team (PACT) initiative, which applies AWS capabilities in analytics, machine learning, compute, storage, security, and cloud data warehousing to Pfizer laboratory, clinical manufacturing and clinical supply chain efforts.

Drug Development 52

Drug Development Small Molecule Synthetic Chemistry Drugs 52

The Pharma Data

OCTOBER 27, 2020

The collaboration aims to leverage Molecular Partners’ proprietary DARPin® technologies and Novartis’ broad expertise in global drug development, regulatory affairs, manufacturing and commercialization to rapidly advance the program in keeping with the unprecedented global urgency created by the pandemic.

Therapies 52

Therapies Virus Treatment Clinical Trials 52